A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)

Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PSUMMIT II
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Jun 2017 Integrated safety results from 3 psoriatic arthritis , 5 Crohns disease, & 4 psoriasis trials presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results evaluating the efficacy of Ustekinumab prior treatment exposure and disease duration in Psoriatic-arthritis patients in PSUMMIT 1 and 2 presented at the 18th Annual Congress of the European League Against Rheumatism
    • 19 Oct 2016 Results of pooled safety analysis from 12 Ustekinumab Crohn's Disease and Psoriatic Diseases trials (n=3636), presented at the 24th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top